Children's Mercy Kansas City

SHARE @ Children's Mercy
Research Days

GME Research Days 2020

May 11th, 11:30 AM - 1:30 PM

Clinical Improvements in a Patient with Spinal Muscular Atrophy
Type 1 Receiving Nusinersen Therapy
Michael D. McDowell Jr
Children's Mercy Hospital and Clinics, mmcdowell@cmh.edu

Follow this and additional works at: https://scholarlyexchange.childrensmercy.org/researchdays
Part of the Higher Education and Teaching Commons, Medical Education Commons, Pediatrics
Commons, and the Science and Mathematics Education Commons

McDowell, Michael D. Jr, "Clinical Improvements in a Patient with Spinal Muscular Atrophy Type 1
Receiving Nusinersen Therapy" (2020). Research Days. 10.
https://scholarlyexchange.childrensmercy.org/researchdays/GME_Research_Days_2020/researchday1/
10

This Poster Presentation is brought to you for free and open access by the CONFERENCES, EVENTS, GRAND
ROUNDS at SHARE @ Children's Mercy. It has been accepted for inclusion in Research Days by an authorized
administrator of SHARE @ Children's Mercy. For more information, please contact library@cmh.edu.

Clinical Improvements in a Patient with Spinal Muscular Atrophy Type 1 Receiving Nusinersen
Therapy
M D McDowell Jr, DO; 1 Z Ehsan, MD 1
Department of Pediatrics, Children's Mercy Kansas City, Kansas City, MO 1;
Introduction:
Spinal muscular atrophy (SMA) is a progressive autosomal-recessive neuromuscular disease and
the most common genetic cause of death during childhood. Nusinersen (Spinraza) was the first
therapy approved in 2016 by the U.S. Food and Drug Administration. Long term data regarding
quality of life outcomes are still lacking. We report a case of a patient with SMA Type 1 receiving
nusinersen with significant clinical improvement.
Case Presentation:
Patient is an eight-year-old male with Type 1 SMA who is gastrostomy tube, tracheostomy and
ventilator dependent started on nusinersen therapy at seven years of age. Prior to therapy, he
was only able to tolerate four to five hours off the ventilator during the daytime and required
assistance during naps. Post therapy, he is able to tolerate being off the ventilator while awake,
can speak, sing, and started swallowing. He required eight admissions for respiratory related
illnesses prior to therapy, with only one since the initiation of nusinersen. Prior to therapy, he
was diffusely hypotonic, could not sit independently, displayed poor fine motor skills, and was
without nearly any oral motor skills. At his most recent visit, he can sit unassisted for 30
minutes, attends school full time, makes clear facial expressions, speaks clearly with his HME in
place, can lift his feet against gravity, and is able to begin weans on his nighttime ventilator
settings.
Discussion:
Children with SMA type 1 develop severe muscle weakness within the first 6 months of life.
Mortality is primarily the result of respiratory failure due to diaphragm involvement.
Nusinersen is an antisense oligonucleotide that promotes production of a full-length protein
from the SMN2 gene, a major determinant of the SMA phenotype. Copy numbers of SMN2
correlate inversely with severity of disease. Phase 3 studies of nusinersen showed variable
response to therapy. The only factors identified that influence response was a) the time
between the first symptoms and the first dose in patients with type 1 SMA and b) the age of
those with type 2 SMA. These factors are likely insufficient to explain variation in outcomes. In
the phase 2 and 3 trial of nusinersen, respiratory outcomes were defined as the use (or not) of
permanent ventilation and did not quantify the number of hours of utilization.
Conclusion:
Long term data regarding achievement of noteworthy milestones such as independent sitting,
weaning off non-invasive ventilator support, number of hospitalizations, versus continued
motor disability and dependence on ventilator support warrant continued evaluation.

